RxDoctor Payments Data

Rahat Hussain, MD

Internal Medicine · Houston, TXNPI 1669620761

Payments from drug & device makers

$240,896in general payments, 2019–2025

Across 168 payments — averaging $1433.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • United Therapeutics Corporation$238K
  • Boehringer Ingelheim$974
  • Abbott$464
  • Merit Medical Systems Inc$187
  • Astellas Pharma US Inc$137
  • Boston Scientific$130
  • plus $602 from 15 others

What the payments were for

  • Consulting fees$6,58660%
  • Travel & lodging$1,43513%
  • Food & beverage$2,88126%
  • Education$30%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$240,896 in reported general payments places this provider in the 95th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$74,595
Medicare patients
145
Services billed
1,136

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OfevNintedanib Esylate96$1,286,158
Tyvaso DpiTreprostinil11$265,141
Orenitram ErTreprostinil Diolamine22$207,068
CresembaIsavuconazonium Sulfate15$102,802
Gamunex-CImmune Globul G/Gly/Iga Avg 4619$85,840
AmbisomeAmphotericin B Liposome21$82,425
Atovaquone79$65,028
OzempicSemaglutide47$60,952
Trelegy ElliptaFluticasone/Umeclidin/Vilanter86$60,265
EliquisApixaban53$40,380
Valganciclovir Hcl61$32,654
Evenity (2 Syringes)Romosozumab-Aqqg12$28,122
Pirfenidone15$21,050
Tacrolimus110$18,804
Voriconazole21$18,411

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat$974$1,299,986119 claims
Astellas Pharma US IncCresemba$137$102,80215 claims
Grifols USA, LLCGamunex-C$39$85,84019 claims
GSKTrelegy Ellipta, Anoro Ellipta$92$69,805108 claims
PfizerEliquis$15$40,38053 claims
AstraZenecaSymbicort, Lokelma$16$17,47653 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →